Kisspeptin-10

KP-10 · KISS1 Gene Fragment · Metastin · GnRH Upstream Regulator

"The pulse generator for the entire reproductive axis — upstream of even GnRH. Kisspeptin neurons in the hypothalamus fire to trigger GnRH release, which triggers LH, which triggers testosterone. Named after Hershey, Pennsylvania (where KISS chocolates are made). Growing fast in the TRT and male fertility community as the most upstream intervention available."

Type

10 aa C-terminal fragment of kisspeptin-54

Position

Upstream of GnRH → LH → testosterone

Status

UK: not illegal to buy or possess · WADA: not specifically listed · US FDA: not approved · Phase II trials in hypogonadism · clinical evidence in hypothalamic amenorrhoea

Half-life

~4–28 min depending on form

Protocol summary

Trial dose

6.4–12.8 nmol/kg SC/IV

Frequency

Pulsatile (~90 min) for fertility

Best evidence

Hypothalamic amenorrhoea

Clinical-trial

6.4–12.8 nmol/kg SC/IV · pulsatile dosing for fertility applications

Off-label community use for TRT support is uncharted territory

How we read the evidence

Master regulator of GnRH release · multiple Phase 1/2 fertility trials · solid clinical evidence in specific reproductive disorders · no community use case for healthy individuals

Animal evidence

Kisspeptin (KISS1 gene product) is the principal upstream regulator of pulsatile GnRH secretion in the hypothalamus — the master switch for the entire reproductive axis. Discovery of its obligate role in human puberty (de Roux et al. 2003; Seminara et al. 2003) revolutionised reproductive endocrinology. Animal work established the dose-response, the receptor (KISS1R/GPR54), and the integration with sex steroid feedback and metabolic cues. Chronic continuous administration causes receptor desensitisation (similar to GnRH agonist behaviour); pulsatile dosing preserves responsiveness.

Community & clinical practice

Limited legitimate community use — kisspeptin is primarily a clinical reproductive medicine compound, not a wellness peptide. Some practitioner-led protocols use single SubQ doses for diagnostic GnRH testing or short courses for hypothalamic amenorrhoea support. Pulsatile dosing every ~90 minutes via infusion pump in fertility settings. Self-administration without medical supervision lacks a clear use case — kisspeptin's effects are downstream of the entire HPG axis, so the relevant context is reproductive medicine rather than performance.

Human trial data

Substantial Phase 1/2 evidence base. Multiple published trials in hypothalamic amenorrhoea showing pulsatile SubQ kisspeptin (every 90 min for 2 weeks, NCT05633966 and NCT07224438) restores LH pulsatility and gonadotropin secretion. A 2-month twice-weekly trial in 10 women with hypothalamic amenorrhoea demonstrated sustained sex-hormone stimulation with response holding from day 14 onward (Endocrinology 2010). Single-dose work shows kisspeptin induces oocyte maturation in IVF settings with lower OHSS risk than HCG triggers. TAK-448 and TAK-683 (kisspeptin receptor agonists) Phase 1 in healthy men showed paradoxical testosterone suppression below castration levels with chronic dosing — illustrating receptor desensitisation. JCEM 2025 work showed kisspeptin does not affect anxiety acutely.

Regulatory status

Not FDA-approved. Available in research and clinical-trial settings, and through some compounding pharmacies in fertility-focused clinics. Side-effect profile favourable — mild headache and nausea, no serious adverse events reported in trials. Long-term safety beyond trial timeframes is unknown. WADA does not list kisspeptin specifically.

Convergence

Kisspeptin has a strong and growing Phase 1/2 evidence base in specific reproductive medicine indications — hypothalamic amenorrhoea, oocyte maturation in IVF, diagnostic GnRH testing. It does not have a wellness or performance use case, and Pep IQ does not endorse community self-administration outside of fertility-medicine context. Pulsatile administration mimicking natural GnRH pulses is the validated framework; chronic continuous dosing causes desensitisation (the basis of pharmacological gonadotropin suppression). For the right reproductive indication under medical supervision, this is one of the more promising emerging compounds; for general wellness, it is not the right tool.

Origin & Background

Named after Hershey, Pennsylvania

Kisspeptin was discovered in 1996 as a tumour suppressor protein encoded by the KISS1 gene — in Hershey, Pennsylvania, home of the Hershey chocolate factory and its famous KISS candies. Its reproductive significance wasn't recognised until 2003, when two independent groups simultaneously discovered that loss-of-function mutations in the kisspeptin receptor (GPR54) caused hypogonadotropic hypogonadism — profoundly low testosterone with failure to go through puberty. The finding established kisspeptin as an essential regulator of the HPG axis.

Kisspeptin-10 is the shortest biologically active fragment of kisspeptin-54 — the full-length form — corresponding to the C-terminal 10 amino acids. Despite being 44 amino acids shorter than kisspeptin-54, KP-10 retains full GPR54 receptor binding and equivalent potency for triggering GnRH release. Its shorter half-life (~4–28 minutes depending on the form) makes it more suitable for pulsatile protocols; kisspeptin-54 has a longer duration of action.

The growing TRT and male fertility community interest stems from a logical argument: if you want to restart or preserve the HPG axis, why start at GnRH (gonadorelin) when you can go even further upstream? Kisspeptin triggers the hypothalamic neurons that release GnRH — addressing the axis at its most fundamental regulatory level. This makes it theoretically attractive for conditions where the hypothalamic pulse generator itself is the problem, not just the GnRH signal.

Science & Mechanism

The pulse generator — upstream of everything

Mechanism of Action

GPR54 receptor activation: Kisspeptin-10 binds GPR54 (now renamed Kiss1R) — a Gq/11-coupled GPCR expressed on GnRH neurons in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus. GPR54 activation triggers phospholipase C → IP3 → intracellular calcium → action potential → GnRH vesicle release into the portal circulation.

GnRH pulse initiation: Kisspeptin neurons are the primary pacemakers of pulsatile GnRH secretion. The ~90-minute GnRH pulse rhythm is driven by kisspeptin neuron firing — making kisspeptin the upstream generator of the entire reproductive pulse pattern. Exogenous kisspeptin-10 mimics this trigger, inducing a GnRH pulse followed by LH and then testosterone rises.

LH surge and testosterone: The GnRH pulse triggered by kisspeptin produces an LH pulse ~15–30 minutes later. In men with intact HPG axes, this LH pulse reliably stimulates Leydig cell testosterone synthesis. In human studies of hypogonadotropic hypogonadism patients, kisspeptin administration produced dose-dependent LH and testosterone rises.

Preserving versus bypassing the axis: Like gonadorelin, kisspeptin works through the natural HPG cascade rather than bypassing it (as HCG does). But kisspeptin goes one step further upstream — it activates the neurons that release GnRH, rather than replacing GnRH itself. This may provide a more complete axis restoration in conditions where the kisspeptin pulse generator is the primary failure point.

Testosterone-independent libido effects: Kisspeptin has direct effects on brain circuits governing sexual motivation and behaviour, independent of the testosterone it induces. GPR54 receptors are expressed in limbic regions associated with sexual behaviour, and kisspeptin has been shown to enhance sexual motivation in animal models and improve sexual function in human studies of patients with hypoactive sexual desire — a mechanism distinct from testosterone.

Human evidence: Multiple academic groups have published studies showing kisspeptin administration produces dose-dependent LH and testosterone rises in healthy men and in patients with hypogonadotropic hypogonadism. A notable 2017 study from Dhillo's group at Imperial College London showed continuous kisspeptin infusion in men with hypogonadotropic hypogonadism restored pulsatile LH secretion in some patients. Studies in healthy men show acute testosterone rises of 50–100% above baseline following KP-10 administration. The data on kisspeptin for sexual desire specifically is growing, with several human studies showing improvements in sexual function scoring independent of testosterone changes.

Benefits & Evidence

What the data shows

🧬

LH and testosterone stimulation

Multiple human studies confirm dose-dependent LH and testosterone rises following KP-10 administration in healthy men and hypogonadal patients. LH rises within 30 minutes; testosterone peaks at 60–90 minutes post-injection.

● Moderate — human studies · not TRT-specific

❤️

Sexual desire — direct central effects

Kisspeptin has GPR54-mediated effects on limbic sexual motivation circuits independent of testosterone. Human studies show improvements in sexual function and desire. Growing evidence base from Dhillo group (Imperial) and others.

● Moderate — human data · mechanism confirmed

👶

Hypogonadotropic hypogonadism

Continuous kisspeptin infusion restored pulsatile LH secretion in some HH patients. Potential alternative to GnRH pump therapy in certain presentations. Research stage — not clinical standard.

● Limited — research stage · small studies

⚾

TRT axis preservation (upstream)

Theoretically superior to gonadorelin as the most upstream intervention — addresses the pulse generator rather than replacing GnRH. Human TRT-specific data thin. Growing community use precedes formal trials.

● Limited — extrapolated · TRT data thin

Things to know

Risks & considerations

Mild

Testosterone/oestrogen elevation — kisspeptin raises testosterone, which aromatises to oestradiol. Monitor E2 especially in men prone to high aromatisation. Aromatase inhibitor adjustment may be needed.

Mild

Injection site reactions — standard SubQ peptide reactions. Rotate sites for twice-weekly or more frequent protocols.

Unknown

Long-term effects on kisspeptin receptor sensitivity — chronic exogenous kisspeptin could theoretically desensitise GPR54 receptors, blunting the body's endogenous pulse generator. Not characterised in humans.